Dong Kook Lifescience, spun off from Dong Kook Pharmaceutical, has started of export in 1992 and has achieved excellent result in overseas sales with US$ 20 Million to 17 countries in 2017.
Our portion of export is over 25% of total sales figure and it holds high rank in Korean pharmaceutical industry.
Dong Kook Lifescience has extended its markets from Asian and Latin American countries to Japan and EU. We exploit the emerging markets including India, China, Africa and Russian Federation which have strong potential for growth.
Despite of the strict regulations for pharmaceutical products of the advanced countries including EU and Japan, we have, for years, made great efforts to have H/W and S/W complied with the European standard and to obtain the regulation from Health Authorities.
As a result of these efforts and investment, export sales to the advanced countries accounts for large portion of the total revenue.
Our major product are 7 in total, raw materials for export are Iopamidol(X-ray contrast medium), Cilastatin(Antibiotics) and etc., finished product Pamiray (X-ray contrast medium), Megaray & Uniray (MRI contrast medium) and etc.
Dong Kook Lifescience focuses on continually reorganizing R&D and production systems in accordance with global market requirements and having experts implement global marketing activities.
With constant development of new products, Dong Kook Lifescience will keep extending markets and products, and strengthening global marketing through Globalization Strategy such as licensing-out and overseas investment.